Cartesian Therapeutics Inc (RNAC)
25.74
+0.14
(+0.55%)
USD |
NASDAQ |
May 06, 16:00
25.74
0.00 (0.00%)
After-Hours: 20:00
Cartesian Therapeutics Enterprise Value: 378.67M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 378.67M |
| May 02, 2024 | 357.85M |
| May 01, 2024 | 325.99M |
| April 30, 2024 | 315.85M |
| April 29, 2024 | 314.60M |
| April 26, 2024 | 297.34M |
| April 25, 2024 | 295.03M |
| April 24, 2024 | 291.82M |
| April 23, 2024 | 289.51M |
| April 22, 2024 | 248.05M |
| April 19, 2024 | 241.82M |
| April 18, 2024 | 230.61M |
| April 17, 2024 | 252.02M |
| April 16, 2024 | 256.82M |
| April 15, 2024 | 260.73M |
| April 12, 2024 | 267.84M |
| April 11, 2024 | 243.84M |
| April 10, 2024 | 213.26M |
| April 09, 2024 | 171.83M |
| April 08, 2024 | 156.36M |
| April 05, 2024 | -3.496M |
| April 04, 2024 | 6.504M |
| April 03, 2024 | 4.188M |
| April 02, 2024 | 10.81M |
| April 01, 2024 | 15.77M |
| Date | Value |
|---|---|
| March 28, 2024 | 30.65M |
| March 27, 2024 | 30.04M |
| March 26, 2024 | 24.18M |
| March 25, 2024 | 33.21M |
| March 22, 2024 | 38.75M |
| March 21, 2024 | 37.07M |
| March 20, 2024 | 47.68M |
| March 19, 2024 | 39.56M |
| March 18, 2024 | 25.42M |
| March 15, 2024 | 17.07M |
| March 14, 2024 | 9.780M |
| March 13, 2024 | 12.16M |
| March 12, 2024 | 18.33M |
| March 11, 2024 | 26.57M |
| March 08, 2024 | 26.74M |
| March 07, 2024 | 27.34M |
| March 06, 2024 | 36.45M |
| March 05, 2024 | 31.97M |
| March 04, 2024 | 33.21M |
| March 01, 2024 | 34.83M |
| February 29, 2024 | 41.54M |
| February 28, 2024 | 39.68M |
| February 27, 2024 | 41.18M |
| February 26, 2024 | 44.54M |
| February 23, 2024 | 41.30M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-3.496M
Minimum
Apr 05 2024
444.30M
Maximum
Jun 14 2021
163.99M
Average
129.30M
Median
Feb 24 2023
Enterprise Value Benchmarks
| Marinus Pharmaceuticals Inc | 5.632M |
| Adial Pharmaceuticals Inc | 4.066M |
| Poseida Therapeutics Inc | 123.31M |
| Viracta Therapeutics Inc | 8.854M |
| Biomea Fusion Inc | 299.00M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -177.66M |
| Revenue (Quarterly) | 8.266M |
| Total Expenses (Quarterly) | 44.60M |
| EPS Diluted (Quarterly) | -41.70 |
| Profit Margin (Quarterly) | -2.15K% |
| Earnings Yield | -193.5% |
| Normalized Earnings Yield | -94.88 |